About TFLL
CT PHARMA RESEARCH BROUGHT ITS QUALITY TO EUROPE
Türkiye is increasing its market share in the world pharmaceutical industry day by day thanks to the private sector.
CT Pharma Research, the leading brand of our country serving in the field of pharmaceutical research and development, has crowned its activities with its quality and experience in Türkiye by moving it to Europe with the new company it established in Belgium. CT Pharma Research, which started its activities in 2012, has managed to become one of the most talked about brands in the sector in a short time with its service diversity and high product quality. Pharmaceutical Biotechnologist Dr. Şerhan ŞİMŞEK and Chemical Engineer Semra AKTAŞ ŞİMŞEK make serious contributions to the country's economy with these investments made with 100% domestic capital. Underlining that they will make a new company investment in the UK in 2018, we talked to Group CEO Dr. Şerhan ŞİMŞEK about their new products and investments they brought to the sector.
Mr. Şerhan, can you tell us about your new investments?
As a company, we are happy to realize our plan to expand abroad, which is one of our short, medium and long-term goals. In line with this goal, which we have established in the past years, we have established a company named TFLL Pharma BVBA, located in Belgium. The legal processes regarding the establishment of the company have been completed. As CT Pharma Research, we will present our products in the fields of equivalent product development, technology transfer, pharmaceutical and biotechnological drugs, food supplements and dermocosmetics to the European market in connection with the Belgian and Belgian market. Our aim here is to use Turkey's existing integration in terms of regulations in the pharmaceutical industry, to offer our products, which we have already developed to the same standards as Europe, to the service of generic drug companies, especially in Europe. CT Pharma Research’s main approach here is self-confidence. It actually means that I am doing my job well and I can do this outside of Türkiye.
Mr. Şerhan, can you tell us about your reasons for choosing Belgium?
Belgium is the logistics center of Europe and a central licensing authority for the pharmaceutical industry. In addition, the headquarters of the world's leading generic and ethical pharmaceutical companies are also located in Belgium. As CT Pharma Research, in addition to having a serious market for our service areas mentioned above, it has also given us a great advantage in being fully integrated with Europe in terms of regulations and regulations applied in Türkiye. We started our activities in Bioville, one of the biggest technoparks in Belgium, as in Türkiye. Our short-term goal here is to enable pharmaceutical companies from India and Asia to receive the services they have purchased from Türkiye. Our medium and long-term goal is to obtain licenses abroad and sell our products and services with our self-confidence, and to expand all over Europe.
Mr. Şerhan, do you have any new plans with your activities abroad?
In the first quarter of 2018, we will establish a company in England. In Saudi Arabia, we signed an agreement with KAUST (King Abdullah University Science And Technology) that will cover local pharmaceutical companies and includes all the services we provide in Türkiye. In the new period, we will continue our work as a global brand that also serves pharmaceutical companies in Saudi Arabia.
Mr. Şerhan, can you tell us the story of the establishment of your company?
After working with my wife Semra Aktaş Şimşek in various R&D positions in the pharmaceutical industry for over twenty years, we decided to establish CT Pharma Research in 2012. Our aim to establish our company was to be an alternative to companies that do not have their own R&D and try to close this gap by obtaining this service or technical files abroad, especially from countries such as India, China and Europe. In 2012, we started laboratory activities in the smallest units in Tübitak Gebze Campus Technology Development Zone. We moved to our laboratory of 100 square meters in the same year, and 200 square meters in 2015, where we are currently operating. We provide turnkey R&D services to 16 domestic and foreign pharmaceutical companies with our formulation development, analytical method development, validation and quality assurance units. The number of projects we have completed has exceeded 140 in five years.
What distinguishes you as an institution from other institutions?
When we established our company, we determined two basic principles. We owe our success today to our uncompromising commitment to these principles. The first of these is that we respect information security and ethical values. Our customer, to whom we provide product development services, is our sponsor, and we undertake that we will not work with any other company after we start working on the molecule or dosage forms that he is considering. Our second fundamental principle is to make our customers, our pharmaceutical companies, feel like CT Pharma Research is their own R&D department. In all projects that come to us, we offer the most economical, most accurate and precise solutions to all problems that our customers will likely encounter at all stages of generic drug research and development activities, from molecule selection to licensing processes.
We can not stop thinking about the future.
We can not stop thinking about the future, it has become a mission that shapes our activities in every field. Accordingly, our primary goal is to be one of the leading companies in this field with our R&D activities in the current account deficit consisting of R&D expenditures and imported drugs. As a company, we are doing everything we can to produce for our country, to work for our country, to produce without being dependent on foreign sources, and we will continue to do so.
WE WILL MAKE A DIFFERENCE IN THE INDUSTRY WITH OUR OWN PRODUCTS
As CT Pharma Research, R&D and licensing processes for our own products, which we mentioned above, have been started. TFLL Pharma will also have an organization that will carry out the sales, marketing, licensing and distribution of the products developed by CT Pharma Research. We have 4 new dermocosmetic products for baby, child and maternal health. It will meet with the consumers as of 2018 with the completely herbal brand PLANTO BABY. When our products in the field of dermocosmetic come to the market, we will have made a serious difference. Because we have developed these products by selecting plants with therapeutic effects to be sold in pharmacies. In addition, we will be on the market with our food supplement products that we plan to use in the field of oncology.
www.ctpharma.com.tr
www.tfllpharma.com